Core Viewpoint - The company reported a significant increase in net profit for Q3 2025, primarily driven by gains from financial assets, despite a decline in year-to-date revenue [1] Financial Performance - In Q3 2025, the company achieved operating revenue of 154 million yuan, representing a year-on-year growth of 3.63% [1] - The net profit attributable to shareholders for Q3 2025 was 20.05 million yuan, showing a substantial year-on-year increase of 143.28% [1] - Year-to-date revenue until the report date was 459 million yuan, reflecting a decline of 15.13% compared to the previous year [1] - The net profit attributable to shareholders for the year-to-date period was 141 million yuan, which is a remarkable year-on-year growth of 943.10% [1] Key Drivers - The significant increase in net profit is mainly attributed to the rise in fair value changes of trading financial assets held by the company, including investments in Shouyao Holdings and Xinghao Pharmaceutical [1]